Payers and employers must evaluate breast cancer screening follow-on diagnostic pattern quality, value

Anna Steere | | Health Imaging | Screening

Higher follow-on diagnostic rates, variation in patterns of follow-on diagnostics, higher breast biopsy rates, and higher false positive biopsy rates due to Affordable Care Act (ACA) provisions demonstrate the need for payer and employer evaluation of the quality and value of breast cancer screening follow-on diagnostic patterns, according to an actuarial analysis published by Milliman on Feb. 20.

Provisions of the ACA are expected to increase breast cancer screening utilization and affiliated follow-on diagnostic testing in the future. However, the broad variation in screening use and testing indicates that better methods are needed to examine suspicious lesions.

Milliman’s analysis reviewed claims from 2009-2011 from MarketScan and identified a study population of about one million women between the ages of 30 and 64 who had undergone mammography screening. Seventeen percent of the studies had follow-on testing, revealing a higher recall rate than that of previous research.

The average screening episode was calculated to be $249.70 for each woman; 62 percent of the cost was from the mammogram and the remaining 38 percent was from follow-on diagnostics. Of the follow-on diagnostics, almost 18 percent were from biopsy, 7.2 percent from follow-up diagnostic mammogram and 4.2 percent from MRI. Less than one percent of the cost was attributed to molecular breast imaging and other procedures.

Additionally, a wide variation in utilization and follow-on diagnostic sequencing was observed. A breast biopsy rate of 2.4 percent was twice that of rates published by the Breast Cancer Surveillance Consortium and a false positive rate of 81 percent was higher than rates reported by the organization as well.

The Milliman report suggests payers and employers review their population’s breast cancer screening recall rates, biopsy rates and evidence of subsequent cancer detection to assess their quality and value of follow-on diagnostic testing.

The report was sponsored by Gamma Medica.

Anna Steere

Related Content

What breast density status can tell us about cardiovascular risk
FDA clears AI tool that flags signs of heart disease in chest CT scans
Patients without PCPs struggle to access lung cancer screening, despite eligibility
Breast cancer rates among women in their 30s are on the rise
Singing radiologist pens song to clear up confusion about breast cancer screening recs
AI loaded onto mammography systems can flag possible cancers in real time to speed workflows

Around the web

Cardiovascular Business
Positron partners with Upbeat Cardiology Solutions to improve cardiac PET/CT access

Positron, a New York-based nuclear imaging company, will now provide Upbeat Cardiology Solutions with advanced PET/CT systems and services. 

Cardiovascular Business
Global shortage of nuclear imaging isotopes may be over

The nuclear imaging isotope shortage of molybdenum-99 may be over now that the sidelined reactor is restarting. ASNC's president says PET and new SPECT technologies helped cardiac imaging labs better weather the storm.

Cardiovascular Business
‘A huge win’: CMS significantly increases Medicare payments for cardiac CT

CMS has more than doubled the CCTA payment rate from $175 to $357.13. The move, expected to have a significant impact on the utilization of cardiac CT, received immediate praise from imaging specialists.